Rafferty Asset Management
PVLA

Rafferty Asset Management’s Palvella Therapeutics PVLA Stock Holding History

Rafferty Asset Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.74M Sell
11,361
-3,229
-22% -$392K ﹤0.01% 677
2026
Q1 		$1.82M Sell
14,590
-1,144
-7% -$119K 0.01% 629
2025
Q4 		$1.65M Buy
+15,734
New +$1.34M 0.01% 692
2022
Q3 		– Sell
-370
Closed -$55K – 1265
2022
Q2 		$55K Buy
370
+90
+32% +$16.4K ﹤0.01% 1097
2022
Q1 		$68K Buy
280
+23
+9% +$6.05K ﹤0.01% 1195
2021
Q4 		$78K Sell
257
-140
-35% -$44.8K ﹤0.01% 1269
2021
Q3 		$164K Buy
+397
New +$138K ﹤0.01% 1199

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Rafferty Asset Management's PVLA Position: Q2 2026 in Review

Rafferty Asset Management reduced its Palvella Therapeutics (PVLA) stake by 22% in Q2 2026, selling an estimated $392K and leaving 11,361 shares worth $1.74M. The position accounts for ﹤0.01% of the portfolio, ranked #677.

Rafferty Asset Management first reported a position in PVLA in Q3 2021 and has held it in 7 quarters since. The position peaked at $1.82M in Q1 2026. 197 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Rafferty Asset Management held 11,361 shares of Palvella Therapeutics worth $1.74M as of Q2 2026.
  • Rafferty Asset Management sold 3,229 Palvella Therapeutics shares in Q2 2026, an estimated $392K.
  • Palvella Therapeutics made up ﹤0.01% of Rafferty Asset Management's portfolio in Q2 2026, its #677 holding.
  • Rafferty Asset Management first reported a position in Palvella Therapeutics in Q3 2021 and has held it in 7 quarters since.
  • Rafferty Asset Management's Palvella Therapeutics position peaked at $1.82M in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Rafferty Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.